Introduction
============

Breast cancer is the most common cancer in the UK, with 150 women being diagnosed every day.[@b1-ppa-11-305] Three quarters of breast cancers contain receptors for estrogen and are known as estrogen receptor positive (ER+). While breast cancer survival rates are increasing, it is still the second most common cause of death from cancer in women.[@b1-ppa-11-305] To increase survival rates and reduce the risk of recurrence, many women with ER+ breast cancer are prescribed hormone therapy (HT), such as tamoxifen, or aromatase inhibitors (AIs), which block the effects of estrogen on cancer cells. Five to ten years of HT significantly reduces rates of cancer recurrence and mortality in women with ER+ early breast cancer.[@b2-ppa-11-305],[@b3-ppa-11-305] Despite significant clinical benefits, many women do not take HT as prescribed, which leads to a significantly increased risk of mortality and recurrence.[@b4-ppa-11-305]--[@b6-ppa-11-305]

Adherence to tamoxifen and AIs ranges from 65% to 79% and 72% to 80%, respectively, but falls over the course of treatment to \~50% by the fourth or fifth year.[@b7-ppa-11-305]--[@b9-ppa-11-305] Furthermore, half of patients discontinue HT by 5 years,[@b10-ppa-11-305],[@b11-ppa-11-305] suggesting that a significant proportion of patients are not receiving the full clinical benefits of HT. An understanding of the mechanisms behind nonadherence would facilitate development of effective interventions, with a view to improving adherence and ultimately increasing the survival benefits associated with HT. Clinical and demographic factors may be useful as identifiable risk factors but cannot be modified through intervention. Psychosocial factors, however, are typically modifiable and are highly suitable targets for intervention. For example, illness and medication perceptions, such as necessity and concern beliefs, are predictive of adherence in other illnesses[@b12-ppa-11-305],[@b13-ppa-11-305] and have been successfully modified.[@b14-ppa-11-305],[@b15-ppa-11-305]

A previous review of HT adherence and persistence concluded that little was known about the impact of clinical, demographic, or psychological factors and highlighted a need to research modifiable factors.[@b16-ppa-11-305] A significant amount of research has been published since 2012, warranting an up-to-date review. In 2015, Cahir et al[@b17-ppa-11-305] carried out a systematic review of modifiable determinants of adherence with a view to developing behavioral interventions. Although the review was useful, there were several limitations, which are addressed by the current review. First, the main conclusions were that side effects, the number of prescription medications and the type of practitioner (general practitioner \[GP\] vs oncologist) influenced HT adherence or persistence. These factors are mostly not suitable for behavior change intervention. A more targeted review of modifiable psychosocial predictors would provide further guidance for the development of an intervention. Second, as gray literature databases and conference abstracts were not included in the search, some key studies are missing from Cahir et al's review. Finally, the authors conducted a meta-analysis, but due to significant heterogeneity, only a very small proportion of studies could be included, limiting the value of the results. For example, although 13 studies investigated the effects of the number of prescription medications, only four studies were eligible for the meta-analysis. Therefore, a narrative synthesis may be more appropriate. Van Liew et al[@b18-ppa-11-305] conducted a narrative synthesis concluding that social support, patient-centered interactions, anxiety and medication beliefs were reliably associated with adherence or persistence. However, this review conducted a limited search of only two databases and may have missed some important eligible studies. Furthermore, empirical interest in this area is growing and a considerable number of studies have been published in the 2 years since the previous reviews.

The current review aims to build upon and address limitations in the previous reviews and identify factors related to HT adherence or persistence by: conducting an updated and broader search to ensure that all relevant articles are identified;searching gray literature databases to identify unpublished literature;combining modifiable psychosocial factors with demographic, clinical and health care factors to provide a comprehensive overview of nonadherence and nonpersistence in this population; andconducting a narrative synthesis as opposed to a meta-analysis, due to the anticipated significant heterogeneity within the included studies.

Methods
=======

Search strategy
---------------

The review was conducted in accordance with PRISMA guidelines.[@b19-ppa-11-305] The following databases were searched from inception to April 2016: MEDLINE, Embase, Web of Science; PsycINFO and CINAHL. Search terms included a combination of terms related to, 1) breast cancer, 2) non-adherence or nonpersistence, and 3) HT. Specific search terms are listed in [Table S1](https://www.dovepress.com/get_supplementary_file.php?f=126651.pdf). Reference lists of included articles were screened, and gray literature databases were searched.

Study selection
---------------

Inclusion/exclusion criteria are shown in [Table 1](#t1-ppa-11-305){ref-type="table"}. Participants had to be female, \>18 years of age and prescribed adjuvant HT for primary breast cancer. Studies had to be conducted in clinical practice, as adherence rates are often higher in clinical trials.[@b20-ppa-11-305] After removing duplicates, one author (ZM) screened titles and abstracts and excluded irrelevant articles. Full texts were then screened for inclusion by two authors (ZM and SC) using a predefined screening table, and one disagreement was resolved. Authors of conference abstracts were contacted to identify unpublished articles, and two authors responded with the full-text articles.

Data extraction
---------------

Information was extracted on study design, participant characteristics, adherence measurement, outcome measures and study results. Data were extracted by one researcher. Another researcher independently extracted data from 10% of articles, and there were no disagreements.

Quality assessment (QA)
-----------------------

The QA tool was adapted from Pasma et al[@b21-ppa-11-305] based on recommendations from Sanderson et al.[@b22-ppa-11-305] Studies were assessed on methods for selecting study participants and measuring study variables, appropriate statistical analyses, loss to follow-up and removal of nonpatient-initiated nonadherence (eg, due to contraindications). Studies scored 1 if they met each criterion and 0 if it was not met or was unclear. The proportion of criteria met was indicated by a percentage, as some criteria were not applicable for all articles. One author (ZM) conducted QA, and another author (SC) verified a random subset of 10% of articles. An additional author (LDH) resolved one discrepancy.

Results
=======

A total of 6,140 articles were identified, and after removing duplicates and screening titles and abstracts, 120 full-text articles were screened. Sixty-one articles were included in the review ([Figure 1](#f1-ppa-11-305){ref-type="fig"}). There was heterogeneity between studies in terms of outcome measures, type of effect sizes, definitions of adherence and predictor variables. It is, therefore, inappropriate to conduct a meta-analysis.

Characteristics of studies
--------------------------

The majority of studies were conducted in North America (n=34) and Europe (n=17; [Table 2](#t2-ppa-11-305){ref-type="table"}). The mean sample size was 3,042 (range 82--26,179), and there were 181,793 unique participants. Two studies included data analyzed from the same sample.[@b23-ppa-11-305],[@b24-ppa-11-305] One study was a follow-up analysis[@b25-ppa-11-305] using the same sample as a previous study.[@b26-ppa-11-305] All studies were included in the review. Studies were cross-sectional (n=16), retrospective (n=32) and longitudinal (n=13). Average follow-up for retrospective and longitudinal studies was 3.1 years (SD =1.4) and 2.7 years (SD =1.4), respectively. Twelve studies included patients prescribed tamoxifen, seven studies included patients prescribed AIs and 42 studies included patients on either therapy. Studies measured nonadherence (n=25), discontinuation/nonpersistence (n=29), or both (n=6). One study measured interruption, defined as a 60-day gap in treatment. Measurements included Medication Event Monitoring System (MEMS; n=2), medical records (n=4), prescription records (n=27), self-report (n=21) and a combination of measures (n=7). Of the studies using self-report, only six studies used validated measures. Nonpersistence was defined as gaps in treatment of 45 days (n=3), 60 days (n=8), 90 days (n=2) and 180 days (n=6).

Risk of bias in included studies
--------------------------------

The average quality score was 74%, ranging from 33% to 100% ([Table 3](#t3-ppa-11-305){ref-type="table"}). The majority of studies were of moderate quality, but there were eleven low- (≤50%) and 22 high-quality (≥80%) studies. Several studies using self-report data had a risk of selection bias, and some studies failed to use validated measures ([Table 3](#t3-ppa-11-305){ref-type="table"}). Only one-third of the studies removed women from analysis who had had a recurrence or died and, therefore, were no longer prescribed HT.

Summary of results
------------------

The percentage of women categorized as adherent ranged from 47% to 97% (mean =74%, SD =13%) and fell from an average of 79% in the first year of treatment to 56% in the fourth or fifth year. Studies using MEMS found the highest adherence rate (93%), followed by self-report (82%) and prescription refill rates (75%). Unintentional nonadherence (eg, forgetting) was specifically measured in three studies and was found to be more common than intentional nonadherence (mean =31% vs 15%).[@b27-ppa-11-305]--[@b29-ppa-11-305] Discontinuation ranged from 9% to 63% (mean =30%, SD =12%). Discontinuation rose from an average of 21% in the first year to 48% in the fifth year. Rates of discontinuation were similar across different measurements (prescription refill, self-report and medical records). In some studies, nonpersistence and nonadherence are clearly separated, making it possible to combine the non-persistence rates (23%--32%) with the nonadherence rates (9%--28%) to calculate the total proportion of the original sample who are not taking their medication as prescribed. In these studies, this amounts to 33%--50% across 2--4 years of treatment, which highlights the extent of the problem of nonadherence in this population.[@b8-ppa-11-305],[@b30-ppa-11-305]--[@b32-ppa-11-305] However, it is not possible to calculate this from other studies due to measurement and classification issues. For example, many studies provide nonadherence figures (using self-report, MEMS and prescription refill) without being explicit as to whether nonpersistent women were removed from analysis or were classed as nonadherent. Others stated that those who discontinued were removed from analysis but have not provided discontinuation rates. Finally, some authors have classed participants who discontinued treatment as nonadherent and some have allowed participants to be both nonpersistent and nonadherent. Therefore, accurate estimates of nonadherence and nonpersistence rates are currently lacking.

Correlates of adherence and persistence
---------------------------------------

A large number of variables showed no significant relationship with HT adherence or persistence ([Table 4](#t4-ppa-11-305){ref-type="table"}). The remaining factors are discussed later. For the purpose of synthesizing results, variables have been classed as having a positive effect, a negative effect, or no effect on adherence/persistence. A positive/negative effect indicates a statistically significant relationship (*P*\<0.05) between adherence or persistence and the predictor variable.

Clinical factors
----------------

### Adherence

The majority of clinical factors showed no consistent associations with adherence or showed mixed results (eg, tumor size, previous chemotherapy and lymph node status). Switching between HTs was associated with decreased adherence in seven studies[@b23-ppa-11-305],[@b28-ppa-11-305],[@b33-ppa-11-305]--[@b37-ppa-11-305] and increased adherence in three studies.[@b8-ppa-11-305],[@b38-ppa-11-305],[@b39-ppa-11-305] The majority of articles did not specify the direction of switching between medications.

Regarding overall side effects, two studies showed a negative relationship with adherence[@b27-ppa-11-305],[@b29-ppa-11-305] and three studies found no significant effects ([Table 5](#t5-ppa-11-305){ref-type="table"}). Hot flushes/vasomotor symptoms, incontinence, gastrointestinal symptoms and sex-related symptoms were not associated with adherence, whereas weight concerns were associated with decreased odds of adherence.[@b40-ppa-11-305],[@b41-ppa-11-305] Cognitive, gynecological, musculoskeletal and sleep/fatigue-related symptoms were associated with lower odds of adherence in some studies, but the effects were not consistently found.[@b40-ppa-11-305]--[@b42-ppa-11-305]

### Persistence

Similar to adherence, the majority of clinical factors were not reliably associated with persistence for the prescribed treatment duration. Three studies found that a codiagnosis of osteoporosis or diabetes was related to increased persistence.[@b43-ppa-11-305]--[@b45-ppa-11-305] However, mixed results were found for the effects of comorbidities in general, with the majority of studies finding no significant associations.

Five studies found that experiencing any/severe side effects was associated with decreased odds of persistence,[@b25-ppa-11-305],[@b35-ppa-11-305],[@b46-ppa-11-305]--[@b48-ppa-11-305] but three studies found no significant effects. Women who experienced menopause-related side effects were up to three times less likely to persist[@b10-ppa-11-305],[@b49-ppa-11-305],[@b50-ppa-11-305] in three studies but more likely to persist with treatment in two studies.[@b48-ppa-11-305],[@b51-ppa-11-305] Hair thinning was associated with increased odds of persistence, but headaches and loss of appetite showed the opposite effect.[@b51-ppa-11-305] Gynecological symptoms were associated with increased odds of persistence in one study,[@b51-ppa-11-305] but another two studies found no significant effects.

Health care factors
-------------------

### Adherence

Consultations with an oncologist or mastologist increased odds of adherence in two studies compared to women without these consultations.[@b9-ppa-11-305],[@b23-ppa-11-305] Experiencing more hospitalizations was associated with lower odds of adherence.[@b9-ppa-11-305],[@b23-ppa-11-305],[@b34-ppa-11-305],[@b36-ppa-11-305] Higher monthly prescription costs were associated with decreased odds of adherence in four studies,[@b30-ppa-11-305],[@b32-ppa-11-305],[@b34-ppa-11-305],[@b52-ppa-11-305] but two studies found no significant effects.

### Persistence

Five studies showed that odds of persistence increased by 21%--66% if treatment was received by an oncologist or a gynecologist as opposed to a general practitioner,[@b32-ppa-11-305],[@b43-ppa-11-305]--[@b45-ppa-11-305],[@b53-ppa-11-305] while two studies found no significant effect. Five studies found that being prescribed more medications per month was associated with increased odds of persistence;[@b7-ppa-11-305],[@b25-ppa-11-305],[@b26-ppa-11-305],[@b54-ppa-11-305],[@b55-ppa-11-305] however, an additional study showed the opposite effect[@b32-ppa-11-305] and three studies found no significant effects. Furthermore, two of the studies showing a positive effect used the same sample at different time points.[@b25-ppa-11-305],[@b26-ppa-11-305] Three studies found that women who were hospitalized more were less likely to persist with treatment,[@b24-ppa-11-305],[@b56-ppa-11-305],[@b57-ppa-11-305] but one study found no significant effects. Women who used complementary or alternative therapies had lower odds of persistence.[@b7-ppa-11-305]

Demographic factors
-------------------

### Adherence

Nine studies showed lower odds of adherence for women under the age of 40/50 years,[@b9-ppa-11-305],[@b23-ppa-11-305],[@b28-ppa-11-305],[@b31-ppa-11-305],[@b33-ppa-11-305],[@b34-ppa-11-305],[@b38-ppa-11-305],[@b39-ppa-11-305],[@b58-ppa-11-305] one study found the opposite,[@b59-ppa-11-305] and three studies showed no significant effects. Six studies found that older women (\>65/75 years) were less likely to be adherent.[@b9-ppa-11-305],[@b30-ppa-11-305]--[@b33-ppa-11-305],[@b59-ppa-11-305] However, two studies found the opposite effect[@b28-ppa-11-305],[@b60-ppa-11-305] and six studies found no effects. Four studies found that being black was associated with lower odds of adherence than being white,[@b8-ppa-11-305],[@b31-ppa-11-305],[@b32-ppa-11-305],[@b52-ppa-11-305] but a further three studies found no significant effects for this relationship.[@b30-ppa-11-305],[@b58-ppa-11-305],[@b61-ppa-11-305]

### Persistence

There was a trend suggesting that younger (\<45/50 years) women had lower odds of persistence,[@b8-ppa-11-305],[@b24-ppa-11-305],[@b43-ppa-11-305],[@b45-ppa-11-305],[@b54-ppa-11-305],[@b60-ppa-11-305],[@b62-ppa-11-305] but this was not always supported. Nine studies showed that older women were less likely to persist with treatment,[@b8-ppa-11-305],[@b11-ppa-11-305],[@b30-ppa-11-305],[@b32-ppa-11-305],[@b48-ppa-11-305],[@b54-ppa-11-305],[@b57-ppa-11-305],[@b62-ppa-11-305],[@b63-ppa-11-305] but seven studies found no significant association and one study found the opposite effect.[@b49-ppa-11-305]

Psychosocial factors
--------------------

The following variables showed significant effects on adherence but were only tested in one study: illness coherence[@b46-ppa-11-305] and self-efficacy regarding learning about medication[@b29-ppa-11-305] (positive effect on adherence) and practical problems associated with medication taking[@b29-ppa-11-305] (negative effect on adherence). Optimism showed a positive effect on persistence,[@b64-ppa-11-305] and expressing a future desire for fertility had a negative effect on persistence.[@b65-ppa-11-305]

### Adherence

There was some evidence suggesting that medication beliefs were related to adherence. Three studies showed that "necessity beliefs", defined as judgments of personal need for the treatment,[@b12-ppa-11-305] were significantly related to increased adherence.[@b35-ppa-11-305],[@b66-ppa-11-305],[@b67-ppa-11-305] The adherence estimator measures perceived need for medication, concerns and affordability and categorizes people as low, medium and high risk for nonadherence. Women who were high risk were more likely to report being nonadherent.[@b42-ppa-11-305] Negative and positive emotions regarding therapy were related to decreased and increased adherence, respectively,[@b35-ppa-11-305],[@b68-ppa-11-305] and perceived importance of therapy was related to increased adherence.[@b61-ppa-11-305] Karmakar[@b69-ppa-11-305] found that coping appraisal, defined as the effectiveness of taking HT and self-efficacy in ability to take HT, minus the costs of taking HT, was associated with increased odds of adherence. Four studies found no effects of necessity beliefs on adherence.[@b27-ppa-11-305],[@b40-ppa-11-305],[@b46-ppa-11-305],[@b68-ppa-11-305] These four studies had small sample sizes and may have lacked power to find a significant effect. However, where effect sizes were given, they were relatively small. Three studies found a positive relationship between perceived self-efficacy for medication taking and adherence.[@b27-ppa-11-305],[@b29-ppa-11-305],[@b69-ppa-11-305]

Variables relating to patient--physician relationship tended to be associated with adherence. Patient--physician relationship quality,[@b35-ppa-11-305] value of doctor's opinion,[@b61-ppa-11-305] frequency of physician communication,[@b67-ppa-11-305] and self-efficacy in patient--physician communication[@b27-ppa-11-305] were positively associated with adherence. However, several of these were only tested in univariate analysis and in single studies.

### Persistence

Having a neutral or negative decisional balance score, ie, believing that the benefits of the treatment do not outweigh the harms, was associated with three times lower odds of persistence within the first 2 years of therapy.[@b26-ppa-11-305] A 5-year follow-up study supported this relationship but with a smaller effect size.[@b25-ppa-11-305] Positive and negative emotions regarding HT were associated with increased/decreased odds of adherence.[@b35-ppa-11-305]

Results for patient--physician relationship were mixed. Two studies found that perceptions of better physician communication were associated with increased odds of persistence,[@b50-ppa-11-305],[@b64-ppa-11-305] but three studies found no significant effects. However, one of these effects was nearing significance.[@b25-ppa-11-305] Being involved in decisions and discussing HT with a doctor were found to have no significant effects on persistence in two studies and a positive effect in one study.[@b48-ppa-11-305] However, being able to ask questions and understanding information,[@b10-ppa-11-305] self-efficacy in patient--physician interaction,[@b50-ppa-11-305] and receiving the right amount of support[@b48-ppa-11-305] were significantly related to increased persistence.

Two studies showed that no longer fearing cancer recurrence was associated with an increased risk of treatment interruption,[@b10-ppa-11-305],[@b55-ppa-11-305] but this did not remain significant in multivariate analysis.[@b55-ppa-11-305] Three studies found that women reporting low levels of social support were less likely to persist with treatment.[@b10-ppa-11-305],[@b64-ppa-11-305],[@b70-ppa-11-305]

Discussion
==========

This article reviewed the evidence for clinical, demographic and psychosocial predictors of HT adherence and persistence to present a holistic view of the evidence base. Empirical interest in this area is growing, and this review builds upon previous reviews by incorporating 27 new studies. One previous review concluded that social support, patient-centered interactions, anxiety and beliefs were related to nonadherence/nonpersistence.[@b18-ppa-11-305] While this current review supports some of these findings, new research has questioned whether anxiety is related to nonadherence. Cahir et al[@b17-ppa-11-305] found that side effects and follow-up care with a GP (vs oncologist) was negatively associated with persistence and the number of medications was positively associated with persistence. This review supported the previous findings that receiving care from an oncologist was associated with increased persistence but found mixed results for the number of medications and side effects. This review also highlighted new factors, such as younger age and hospitalizations, and moved beyond these findings to identify modifiable factors, such as self-efficacy for medication taking.

Researchers and clinicians often assume that side effects, especially menopausal symptoms, trigger nonadherence.[@b71-ppa-11-305],[@b72-ppa-11-305] Although some studies found a relationship between side effects and adherence/persistence, the relationship was not always supported.[@b73-ppa-11-305] However, studies investigating the effects of hot flushes were low to moderate quality, so further high-quality research is needed. Several studies found that nonadherent or nonpersistent women reported fewer side effects, possibly as a result of not taking the medication. Future research should therefore measure adherence and side effects at several time points to see how the relationship changes across time. Qualitative research has shown that some women would not discontinue HT regardless of its side effects (Moon Z, Moss-Morris R, Hunter M, Hughes L., unpublished data, 2017), which may account for the inconsistent relationship between side effects and adherence.

Being treated by specialists rather than a general practitioner increased persistence. These physicians may provide more specialized and informed care,[@b43-ppa-11-305] leading to women being more educated and having positive treatment beliefs, although this was not measured directly. An intervention focusing on knowledge and beliefs may support women who did not receive this from their physician. This is supported by the studies showing that medication beliefs are related to adherence levels.[@b26-ppa-11-305],[@b35-ppa-11-305] Furthermore, several studies showed that variables relating to the patient--physician relationship and physician communication were associated with increased odds of adherence. These results suggest that training primary care physicians to provide more specialized care could improve adherence rates.

Some evidence suggested that women whose insurance data indicated nonadherence or nonpersistence over 1--5 years were more likely to have been hospitalized over the same period. These women may have not taken their medication while in hospital, but as no data were provided for adherence levels during the hospitalization, no strong conclusions can be made. There was relatively consistent evidence from moderate- to high-quality studies, suggesting that younger women had lower odds of adherence and slightly less consistent evidence for a relationship between younger age and nonpersistence. This is in line with previous reviews into adherence in cancer and other illnesses.[@b74-ppa-11-305],[@b75-ppa-11-305] Young women may not take HT due to issues around early menopause or fertility[@b24-ppa-11-305] as HT precludes conception. In addition, young women do not adjust as well to a cancer diagnosis, which may affect adherence.[@b54-ppa-11-305],[@b76-ppa-11-305] Results were mixed for the relationship between older age and adherence or persistence.

In terms of modifiable factors, three studies found that women who reported few sources of social support were more likely to discontinue treatment. The importance of social support in maintaining adherence has been highlighted previously,[@b77-ppa-11-305],[@b78-ppa-11-305] but social support was only found to relate to persistence in this review. Discussing the importance of maintaining good social networks and disclosure of cancer status may increase levels of perceived social support. Several studies have shown promise for the effectiveness of social support interventions.[@b79-ppa-11-305],[@b80-ppa-11-305] Self-efficacy for medication taking, defined as the patient's confidence in their ability to take the medication as prescribed, was associated with increased odds of self-reported adherence.[@b27-ppa-11-305] Self-efficacy for medication taking could be modified by teaching patients strategies to remember to take their medication and helping patients to overcome other practical barriers through modeling, goal setting, or confidence building. Similar interventions have been successful at improving self-efficacy for physical activity and dietary behaviors.[@b81-ppa-11-305],[@b82-ppa-11-305]

Patients who held stronger beliefs regarding how efficacious, necessary, important and affordable HT is were more likely to have higher self-reported adherence, as were women who reported more positive emotions around HT. In addition, women who felt that the risks of the treatment outweighed the benefits were three times more likely to discontinue. This relationship between beliefs and adherence is supported by the Necessity Concerns Framework (NCF) and has been demonstrated previously.[@b83-ppa-11-305],[@b84-ppa-11-305] The NCF suggests that adherence is related to holding high perceptions of the necessity of the medication and low concerns. These beliefs are often shown to be more powerful predictors of adherence than clinical or sociodemographic characteristics and have been successfully modified through intervention.[@b35-ppa-11-305],[@b83-ppa-11-305],[@b85-ppa-11-305] However, the studies investigating beliefs in this review were low- to moderate-quality cross-sectional studies and some used unvalidated measures. In addition, while medication concerns are often found to be predictive of adherence,[@b83-ppa-11-305] the majority of studies found nonsignificant results. This suggests that it may be more important to measure how people weigh up their concerns against their necessity beliefs.

The variability between studies may reflect the heterogeneous populations studied. There were discrepancies in geographic location, health care systems and clinical characteristics. Furthermore, while several studies recruited patients at the initiation of treatment, many studies did not specify the stage of treatment. Research has shown that determinants of adherence vary significantly over time.[@b10-ppa-11-305] Therefore, future research should try to recruit patients at the same time point, explicitly state participants' stage of treatment and follow them over the duration of the prescription period.

The results from this review suggest that there are no strong predictors of HT adherence or persistence. Reviewing high-quality studies in isolation (n=22) reflected this pattern of inconsistent results. However, the high-quality studies did support the trend of higher rates of discontinuation in older women and lower adherence in black women, suggesting a need to further investigate these relationships. The majority of predictors investigated, such as age, are not amenable to change through intervention. Future research is needed to identify psychosocial factors that have been shown to impact on adherence in other conditions. For example, illness perceptions have been shown to be predictive of adherence in other illnesses but have not been investigated fully in HT adherence.[@b12-ppa-11-305],[@b86-ppa-11-305] This review identified one study investigating illness perceptions, which found that coherence beliefs, ie, patients' ratings of their understanding of their breast cancer, were the only significant predictors of nonadherence in multivariate analysis.[@b46-ppa-11-305] Self-efficacy for taking medication, social support and medication beliefs provide potential targets for intervention. However, higher quality research is needed in order to clarify the relationship between medication beliefs and adherence. Interventions could also focus on training clinicians and general practitioners to improve patient--physician communication.

There are several limitations to this review. It was not possible to conduct a meta-analysis due to significant heterogeneity between studies. This heterogeneity also makes it difficult to compare across studies and make conclusions based on significant predictors of nonadherence. Although a wide search was conducted and attempts were made to identify gray literature, some relevant articles may not have been identified. The conclusions are limited by the methodological quality of the included studies. There was a risk of selection bias in some studies, which means a subset of the population who are potentially more at risk of nonadherence may not be included. Sixteen studies were cross-sectional which limits assumptions about causality. Two studies used MEMS to measure adherence and found very high levels, most likely due to the Hawthorne effect where adherence increases because patients know that they are being monitored.[@b87-ppa-11-305] The most common measurement of adherence and persistence was prescription refill, which is known to be the most objective measure.[@b88-ppa-11-305] However, this measurement is still flawed, as we do not know if the patient actually took their medication. Several studies used physician ratings, which are likely to grossly overestimate adherence levels.[@b89-ppa-11-305] Self-report measures are also susceptible to overreporting due to social desirability. Four studies overcame these limitations somewhat by using validated questionnaires.

There are several reasons that a patient may be recommended by their physician to discontinue treatment, such as recurrence and contraindications. These patients should not be classified in the same way as women who choose to discontinue HT and should be removed from analysis. Around a third of studies attempted to adjust for this by removing women who had a recurrence or who died. Seven studies did not allow patients to switch medications and still be considered persistent, and 13 studies were unclear as to whether they allowed this. Furthermore, only a few studies have clearly distinguished between nonadherence and nonpersistence and provided independent figures for both. Without this information, it is not possible to determine the full medication-taking behavior of these patients and, therefore, the clinical impact. The behaviors and outcomes of completely stopping treatment and occasionally skipping doses are different, so it is important to understand these as independent with unique predictors. Future research needs to be clear about how nonadherence rates are classified and ideally to provide independent rates for nonadherence and nonpersistence.

Conclusion
==========

Understanding the determinants of nonadherence is essential when designing interventions to improve HT adherence and ensuring that patients realize the full benefits of HT. The main conclusions that can be drawn from this review are that while clinical and demographic factors may be useful in order to identify women at risk of nonadherence, extensive research has not yet identified any consistent predictors. There was some evidence that increased adherence was related to younger age, fewer hospitalizations and better patient--physician relationship, but these relationships were not always supported. Persistence was related to receiving treatment from a specialist. In terms of modifiable factors, there was some evidence to suggest that beliefs about HT, social support and self-efficacy for taking medication were related to adherence and persistence. In order to guide effective interventions to improve HT adherence and persistence, future research should focus on these factors and on identifying additional potentially modifiable factors, which have been shown to be related to adherence in other illnesses.[@b13-ppa-11-305] Furthermore, strategies to improve patient--physician relationship and service delivery should be investigated.
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###### 

Inclusion and exclusion criteria for studies in the review

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Inclusion criteria                                                                                                         Exclusion criteria
  -------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------
  Patients were all female and aged \>18 years\                                                                              Articles not in the English language or where the full text was not available\
  Patients had been prescribed adjuvant HT to treat primary breast cancer\                                                   Studies including only DCIS or stage IV patients\
  Studies had to be conducted in clinical practice\                                                                          Studies using an intervention to improve adherence\
  Studies had to present statistical tests of association between HT adherence or persistence and a correlate or predictor   Studies investigating initiation to HT\
                                                                                                                             Studies not providing primary data

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** DCIS, ductal carcinoma in situ; HT, hormone therapy.

###### 

Study characteristics

  Study references                        Design (and length of follow-up)                                                N enrolled (N in analysis)   Setting           Age (years)                     Other patient characteristics                                                  Medication          Defining nonadherence or nonpersistence                                    Measurement of nonadherence or nonpersistence
  --------------------------------------- ------------------------------------------------------------------------------- ---------------------------- ----------------- ------------------------------- ------------------------------------------------------------------------------ ------------------- -------------------------------------------------------------------------- -----------------------------------------------
  Aiello Bowles et al[@b51-ppa-11-305]    Cross-sectional                                                                 693 (598)                    USA               52+                             90% Caucasian, stage I--IIB, postmenopausal                                    AIs/TAM             Nonpersistence (no longer using drug at 5 years)                           Self-report
  Barron et al[@b54-ppa-11-305]           Longitudinal (3.5 years)                                                        2,816 (2,346)                Ireland           35+                             Recruited at initiation of therapy                                             TAM                 Nonpersistence (180 days no supply)                                        Prescription refill data
  Bender et al[@b40-ppa-11-305]           Longitudinal (18 months)                                                        91                           USA               57                              88% Caucasian, stage I--IIIa, ER+, recruited at initiation of therapy          AIs/TAM             Adherence (% MPR)                                                          MEMS
  Bhatta et al[@b61-ppa-11-305]           Cross-sectional                                                                 381 (197)                    USA               \<80                            72% Caucasian, stage I--III, ER+                                               AIs/TAM             Persistence (5 years of therapy)                                           Self-report
  Brito et al[@b23-ppa-11-305]            Retrospective (3.3 years)                                                       5,861 (5,861)                Brazil            58                              Stage I--IV                                                                    AIs/TAM (64% TAM)   Nonadherence (MPR \<80%)                                                   Prescription refill data
  Brito et al[@b24-ppa-11-305]            Retrospective (5 years)                                                         5,861 (5,861)                Brazil            58                              Stage I--IV                                                                    AIs/TAM (64% TAM)   Nonpersistence (60 days no supply)                                         Prescription refill data
  Cheung et al[@b90-ppa-11-305]           Retrospective (3 years)                                                         5,150 (5,150)                USA               76                              88% Caucasian, Medicare beneficiaries                                          AIs/TAM (22% TAM)   Nonadherence (PDC \<80%), nonpersistence (60 days no supply)               Prescription refill data
  Cluze et al[@b10-ppa-11-305]            Longitudinal (2 years)                                                          218 (196)                    France            18--40                          Stage I--III, premenopausal, HR+, recruited at initiation of therapy           TAM                 Interruptions (2+ months no refill)                                        Prescription refill data
  Corter[@b46-ppa-11-305]                 Longitudinal (3 months)                                                         125 (120)                    NZ                56                              Stage I--III, HR+                                                              AIs/TAM (74% TAM)   Adherence (never missed a dose)                                            Self-report
  Danilak and Chambers[@b91-ppa-11-305]   Retrospective (2 years)                                                         346 (346)                    Canada            n/s                             Stage I--III, HR+                                                              AIs/TAM (81% TAM)   Nonpersistence (no longer taking drug)                                     Prescription refill data
  Demissie et al[@b47-ppa-11-305]         Longitudinal (3 years)                                                          303 (292)                    n/s               55+                             Stage I--II, 76% ER+, recruited at initiation of therapy                       TAM                 Nonpersistence (no longer taking TAM)                                      Telephone interview
  Fink et al[@b26-ppa-11-305]             Longitudinal (2 years)                                                          690 (516)                    USA               65+                             Stage I--IIIa, ER+, recruited at initiation of therapy                         TAM                 Nonpersistence (no longer taking TAM)                                      Telephone interview
  Font et al[@b38-ppa-11-305]             Retrospective (5 years)                                                         692 (692)                    Spain             n/s                             Stage I--IIIa, HR+, recruited at initiation of therapy                         AIs/TAM             Adherence (MPR =80%--110%)                                                 Various
  Friese et al[@b55-ppa-11-305]           Longitudinal (4 years, cross-sectional analysis for psychological predictors)   3,133 (539)                  USA               59                              48% Caucasian, stage I--III, HR+, recruited at initiation of therapy           HT                  Persistence (taken medication in past week)                                Self-report
  Grunfeld et al[@b66-ppa-11-305]         Cross-sectional                                                                 116 (110)                    UK                35--65                          93% Caucasian                                                                  TAM                 Adherence (taken drugs every day in past week)                             Self-report
  Guth et al[@b53-ppa-11-305]             Retrospective (3 years)                                                         685 (677)                    Switzerland       30--80                          Stage I--III, HR+                                                              AIs/TAM (69% TAM)   Nonpersistence (did not complete therapy)                                  Medical records
  Hadji et al[@b43-ppa-11-305]            Retrospective (3 years)                                                         12,412 (12,412)              Germany           64                              Postmenopausal, HR+, recruited at initiation of therapy                        AIs/TAM (59% TAM)   Nonpersistence (90 days no supply)                                         Prescription refill data
  He et al[@b62-ppa-11-305]               Retrospective (5 years)                                                         3,395 (3,395)                Sweden            4% \<40, 61% 40--64, 35% \>65   Stage I--III, 70% postmenopausal, ER+                                          HT                  Nonpersistence (180 days gap)                                              Prescription refill data
  Hershman et al[@b8-ppa-11-305]          Retrospective (4.5 years)                                                       8,769 (8,769)                USA               n/s                             76% Caucasian, stage I--III, HR+                                               AIs/TAM             Nonadherence (MPR \<80%) and nonpersistence (180 days no supply)           Prescription refill data
  Hershman et al[@b30-ppa-11-305]         Retrospective (2 years)                                                         4,426 (4,426)                USA               50+                             60% Caucasian, stage I--III                                                    AIs                 Nonpersistence (gap of 45 days) and adherence (MPR \>80%)                  Prescription refill data
  Hershman et al[@b31-ppa-11-305]         Retrospective (2 years)                                                         10,302 (10,302)              USA               61                              79% Caucasian, stage I--III                                                    HT                  Nonadherence (MPR \<80%) and nonpersistence (45 days no supply)            Prescription refill data
  Hsieh et al[@b39-ppa-11-305]            Retrospective (4 years)                                                         26,179 (26,179)              Taiwan            52                              n/s                                                                            AIs/TAM (70% TAM)   Nonadherence (MPR \<80%)                                                   Prescription refill data
  Huiart et al[@b70-ppa-11-305]           Longitudinal (2 years)                                                          288 (246)                    France            18--40                          Stage I--III, recruited at initiation of therapy                               TAM                 Nonpersistence (90 days no supply)                                         Prescription refill data
  Huiart et al[@b7-ppa-11-305]            Retrospective (3 years)                                                         382 (233)                    France            65+                             Stage I--III, postmenopausal, recruited at initiation of therapy               AIs                 Nonpersistence (90 days no supply)                                         Prescription refill data
  Jacob Arriola et al[@b67-ppa-11-305]    Cross-sectional                                                                 206 (200)                    USA               59                              55% Caucasian, stage I--IV, HR+                                                AIs/TAM             Adherence (range of scores 0--10)                                          Self-report (MARS)
  Kahn et al[@b48-ppa-11-305]             Cross-sectional                                                                 881 (881)                    USA               21--80                          85% Caucasian, stage I--III, 92% HR+                                           TAM                 Persistence (ongoing use)                                                  Self-report
  Karmakar[@b69-ppa-11-305]               Cross-sectional                                                                 288 (138)                    USA               40--79                          90% Caucasian                                                                  AIs                 Adherence (range of scores 0--8)                                           Self-report (MMAS)
  Kemp et al[@b49-ppa-11-305]             Retrospective (5 years)                                                         1,531 (1,531)                Australia         45+                             n/s                                                                            AIs/TAM (60% TAM)   Nonpersistence (180 days no supply)                                        Prescription refill data
  Kimmick et al[@b92-ppa-11-305]          Retrospective (1 year)                                                          1,491 (951)                  USA               67                              59% Caucasian, stage I--III, HR+/unknown, recruited at initiation of therapy   AIs/TAM (88% TAM)   Adherence (MPR \>80%) and persistence (no gaps of \>90 days)               Prescription refill data
  Kimmick et al[@b27-ppa-11-305]          Cross-sectional                                                                 124 (112)                    USA               64                              91% Caucasian, postmenopausal, HR+, stage I--III                               AIs/TAM (18% TAM)   Intentional/unintentional nonadherence (based on scores)                   MMAS
  Kostev et al[@b45-ppa-11-305]           Retrospective (3 years)                                                         3,620 (3,620)                Germany           60                              Recruited at initiation of therapy                                             TAM                 Nonpersistence (90 days no supply)                                         Prescription refill data
  Kostev et al[@b44-ppa-11-305]           Retrospective (3 years)                                                         3,424 (3,424)                Germany           61                              n/s                                                                            AIs/TAM (61% TAM)   Nonpersistence (180 days no supply)                                        Prescription refill data
  Krotneva et al[@b56-ppa-11-305]         Retrospective (5 years)                                                         3,180 (3,180)                Canada            70+                             Treated with BCS (no chemo/mastectomy)                                         AIs/TAM (81% TAM)   Nonpersistence (60 days no supply)                                         Prescription refill data
  Kuba et al[@b93-ppa-11-305]             Retrospective (5 years)                                                         686 (686)                    Japan             56                              All Asian race, stage I--III, HR+                                              HT                  Persistence (currently taking medication)                                  Medical records
  Lash et al[@b25-ppa-11-305]             Longitudinal (5 years)                                                          462 (462)                    USA               65+                             Stage I--IIIA, 87% ER+, recruited at initiation of therapy                     TAM                 Nonpersistence (stopped taking TAM)                                        Interview questions
  Lee et al[@b33-ppa-11-305]              Retrospective (2 years)                                                         609 (609)                    Seoul             54                              Asian women, 89% ER+, no metastasis                                            AIs                 Adherence (no gaps of \>60 days and MPR \>80%)                             Prescription refill data
  Liu et al[@b50-ppa-11-305]              Longitudinal (3 years)                                                          921 (669)                    USA               51                              34% Caucasian, stage I--III, newly diagnosed                                   HT                  Persistence (hormone use)                                                  Self-report
  Livaudais et al[@b94-ppa-11-305]        Cross-sectional                                                                 3,575 (3,575)                USA               69                              92% Caucasian, postmenopausal, HR+                                             HT                  Persistence (how long taking the medication)                               Self-report
  Llarena et al[@b65-ppa-11-305]          Cross-sectional                                                                 515 (515)                    USA               \<45                            71% Caucasian, stage I--III, HR+, premenopausal                                TAM                 Nonpersistence (no longer taking medication)                               Chart review
  Nekhlyudov et al[@b57-ppa-11-305]       Retrospective (3 years)                                                         2,207 (2,207)                USA               18+                             Stage I--III                                                                   AIs/TAM             Nonpersistence (180 days no supply)                                        Prescription refill data
  Neugut et al[@b32-ppa-11-305]           Retrospective (1 year)                                                          22,160 (22,160)              USA               67                              90% Caucasian, stage I--III                                                    AIs                 Nonadherence (MPR \<80%) and nonpersistence (45 days no supply)            Prescription refill data
  Owusu et al[@b11-ppa-11-305]            Longitudinal (5 years)                                                          961 (961)                    USA               65+                             80% Caucasian, stage I--IIB, ER+/indeterminate, newly diagnosed                TAM                 Nonpersistence (60 days no supply)                                         Medical records
  Partridge et al[@b9-ppa-11-305]         Retrospective (4 years)                                                         2,378 (2,378)                USA               75                              83% Caucasian, stage I--III, recruited at initiation of therapy                TAM                 Nonadherence (MPR \<80%)                                                   Prescription refill data
  Riley et al[@b52-ppa-11-305]            Retrospective (1 year)                                                          9,446 (9,446)                USA               65+                             81% Caucasian, stage I--III, HR+, entitled to Medicare part D                  HT                  Nonadherence (MPR \<80%)                                                   Prescription refill data
  Schmidt et al[@b60-ppa-11-305]          Retrospective (1 year)                                                          4,626 (4,626)                Germany           n/s                             Stage I--IV, postmenopausal HR+                                                AIs/TAM (40% TAM)   Nonpersistence (discontinued)                                              Medical records
  Schover et al[@b42-ppa-11-305]          Cross-sectional                                                                 129 (129)                    USA               64                              81% Caucasian, stage I--IIA, node negative                                     AIs                 Adherence (how many days taken it/discontinued)                            Self-report
  Sedjo and Devine[@b34-ppa-11-305]       Retrospective (1 year)                                                          13,593 (13,593)              USA               \<65                            Postmenopausal, recruited at initiation of therapy                             AIs                 Nonadherence (MPR \<80%)                                                   Prescription refill data
  Seneviratne et al[@b59-ppa-11-305]      Retrospective (4 years)                                                         1,149 (1,149)                New Zealand       60 (24--99)                     80% NZ European, stage I--III, HR+, newly diagnosed                            AIs/TAM (58% AI)    Nonadherence (MPR \<80%)                                                   Prescription refill data
  Sheppard et al[@b64-ppa-11-305]         Longitudinal (3 years)                                                          1,062 (1,062)                USA               65+                             89% Caucasian, stage I--III, ER+, recruited at initiation of therapy           HT                  Nonpersistence (discontinued)                                              Self-report
  Simon et al[@b95-ppa-11-305]            Cross-sectional                                                                 176 (161)                    Canada            57                              ER+                                                                            AIs/TAM             Adherence (MPR \>80%)                                                      Interview questions
  Stanton et al[@b35-ppa-11-305]          Cross-sectional                                                                 2,341 (1,465)                USA               56                              Stage I--IV, 94% Caucasian, HR                                                 AIs/TAM (28% TAM)   Adherence (total MMAS score)                                               Self-report (MMAS)
  Tinari et al[@b28-ppa-11-305]           Cross-sectional                                                                 939 (939)                    Italy             62                              70% postmenopausal                                                             AIs/TAM (29% TAM)   Nonadherence (if not taken medication at least four times in past month)   Self-report
  Trabulsi et al[@b36-ppa-11-305]         Retrospective (5 years)                                                         4,715 (4,715)                Canada            65+                             Stage I--III, recruited at initiation of therapy                               AIs/TAM (95% TAM)   Nonpersistence (60 days no supply)                                         Prescription refill data
  van Herk-Sukel et al[@b63-ppa-11-305]   Retrospective (5 years)                                                         1,451 (1,451)                the Netherlands   n/s                             Stage I--III, 77% HR+, recruited at initiation of therapy                      AIs/TAM             Nonpersistence (60 days no supply)                                         Prescription refill data
  Walker et al[@b68-ppa-11-305]           Cross-sectional                                                                 82 (82)                      USA               39 (22--45)                     90% Caucasian, stage 0--IV, diagnosed \<40, HR+                                AIs/TAM (89% TAM)   Nonadherence (score 7+ on MMAS)                                            MMAS
  Wickersham et al[@b41-ppa-11-305]       Longitudinal (6 months)                                                         198 (198)                    Pittsburgh        59                              98% Caucasian, stage I--III, recruited at initiation of therapy                AIs/TAM (15% TAM)   Nonadherence (MPR \<80%)                                                   MEMS
  Wigertz et al[@b37-ppa-11-305]          Retrospective (3 years)                                                         2,071 (1,741)                Sweden            n/s                             Stage I--III, ER+, recruited at initiation of therapy                          AIs/TAM             Adherence (MPR \>80%)                                                      Prescription refill data
  Wouters et al[@b29-ppa-11-305]          Cross-sectional                                                                 241 (241)                    the Netherlands   57                              n/s                                                                            AIs/TAM (45% AI)    Adherence (dichotomized as \>80% of score distribution)                    Self-report (MARS and MMAS)
  Wu et al[@b58-ppa-11-305]               Retrospective (4 years)                                                         612 (331)                    USA               62                              41% Caucasian, stage I--III, HR+/unknown, recruited at initiation of therapy   AIs/TAM (45% TAM)   Adherence (MPR \>80%)                                                      Prescription refill data
  Ziller et al[@b96-ppa-11-305]           Retrospective (1 year)                                                          100 (89)                     Germany           68                              Postmenopausal, recruited at initiation of therapy                             AIs/TAM (50% TAM)   Adherence (MPR \>80%)                                                      Prescription refill data
  Zeeneldin et al[@b97-ppa-11-305]        Cross-sectional                                                                 139 (139)                    Egypt             50                              Stage I--IV, HR+, during Ramadan                                               AIs/TAM (64% TAM)   Adherence (MPR \<80%)                                                      Interview questions

###### 

Quality assessment

  References                              A   B   C   D   E   F   G   H   I     Percentage
  --------------------------------------- --- --- --- --- --- --- --- --- ----- ------------
  Aiello Bowles et al[@b51-ppa-11-305]    1   1   1   1   0   1   1   0   n/a   75
  Barron et al[@b54-ppa-11-305]           0   1   1   1   1   1   1   0   1     78
  Bender et al[@b40-ppa-11-305]           1   0   1   1   0   1   1   0   0     56
  Bhatta et al[@b61-ppa-11-305]           1   1   0   0   1   0   1   0   n/a   50
  Brito et al[@b23-ppa-11-305]            1   1   1   1   1   1   1   0   0     78
  Brito et al[@b24-ppa-11-305]            1   1   1   1   1   1   1   0   1     89
  Cheung et al[@b90-ppa-11-305]           1   1   1   1   1   1   1   1   1     100
  Cluze et al[@b10-ppa-11-305]            1   0   1   0   1   1   1   1   1     78
  Corter[@b46-ppa-11-305]                 1   1   0   1   1   1   1   0   1     78
  Danilak and Chambers[@b91-ppa-11-305]   1   1   1   1   1   1   1   0   1     89
  Demissie et al[@b47-ppa-11-305]         1   1   0   1   1   1   1   1   0     78
  Fink et al[@b26-ppa-11-305]             1   0   1   0   1   1   1   0   1     67
  Font et al[@b38-ppa-11-305]             1   1   1   1   1   1   1   1   0     89
  Friese et al[@b55-ppa-11-305]           1   1   0   1   1   1   1   1   1     89
  Grunfeld et al[@b66-ppa-11-305]         0   0   1   1   0   0   1   0   n/a   38
  Guth et al[@b53-ppa-11-305]             1   1   0   1   1   1   1   1   1     89
  Hadji et al[@b43-ppa-11-305]            1   1   1   1   1   1   1   0   0     78
  He et al[@b62-ppa-11-305]               1   1   1   1   1   1   1   1   1     100
  Hershman et al[@b8-ppa-11-305]          1   1   1   1   1   1   1   1   1     100
  Hershman et al[@b30-ppa-11-305]         0   1   1   1   1   1   1   0   0     67
  Hershman et al[@b31-ppa-11-305]         1   1   1   1   1   1   1   0   1     89
  Hsieh et al[@b39-ppa-11-305]            1   1   1   1   1   1   1   0   1     89
  Huiart et al[@b70-ppa-11-305]           1   1   1   1   1   1   1   1   1     100
  Huiart et al[@b7-ppa-11-305]            1   1   1   1   1   1   1   1   0     89
  Jacob Arriola et al[@b67-ppa-11-305]    1   0   1   1   1   1   1   1   0     78
  Kahn et al[@b48-ppa-11-305]             1   0   0   0   1   1   1   1   n/a   63
  Karmakar[@b69-ppa-11-305]               1   0   1   1   0   1   1   1   n/a   75
  Kemp et al[@b49-ppa-11-305]             1   1   1   1   1   1   1   1   1     100
  Kimmick et al[@b92-ppa-11-305]          1   1   1   1   1   1   1   0   1     89
  Kimmick et al[@b27-ppa-11-305]          1   1   1   1   1   1   1   0   1     89
  Kostev et al[@b45-ppa-11-305]           1   1   0   1   1   1   1   0   0     67
  Kostev et al[@b44-ppa-11-305]           0   1   0   1   1   1   1   0   0     56
  Krotneva et al[@b56-ppa-11-305]         0   1   1   1   1   1   1   0   0     66
  Kuba et al[@b93-ppa-11-305]             1   1   0   1   0   0   1   0   0     44
  Lash et al[@b25-ppa-11-305]             1   0   0   0   1   1   1   0   0     44
  Lee et al[@b33-ppa-11-305]              1   1   1   1   1   1   1   1   1     100
  Liu et al[@b50-ppa-11-305]              1   0   0   1   1   0   1   0   0     44
  Livaudais et al[@b94-ppa-11-305]        1   1   0   1   1   1   1   0   n/a   75
  Llarena et al[@b65-ppa-11-305]          1   1   1   1   1   1   1   1   n/a   100
  Nekhlyudov et al[@b57-ppa-11-305]       1   1   1   1   1   1   1   0   0     78
  Neugut et al[@b32-ppa-11-305]           1   1   1   1   1   1   1   1   1     100
  Owusu et al[@b11-ppa-11-305]            1   1   0   1   1   1   1   1   0     78
  Partridge et al[@b9-ppa-11-305]         1   1   1   1   1   1   1   1   1     100
  Riley et al[@b52-ppa-11-305]            1   1   1   1   1   1   1   0   0     78
  Schmidt et al[@b60-ppa-11-305]          1   1   0   1   1   1   1   0   0     67
  Schover et al[@b42-ppa-11-305]          0   1   0   1   0   1   0   0   n/a   38
  Sedjo and Devine[@b34-ppa-11-305]       1   1   1   1   1   1   1   0   0     78
  Seneviratne et al[@b59-ppa-11-305]      1   1   1   1   1   1   1   0   0     78
  Sheppard et al[@b64-ppa-11-305]         1   1   0   1   1   1   1   1   0     78
  Simon et al[@b95-ppa-11-305]            1   0   1   1   1   1   1   0   n/a   75
  Stanton et al[@b35-ppa-11-305]          1   0   1   1   1   1   1   0   n/a   75
  Tinari et al[@b28-ppa-11-305]           0   1   0   0   1   1   1   0   n/a   50
  Trabulsi et al[@b36-ppa-11-305]         1   1   1   1   1   1   1   1   0     89
  van Herk-Sukel et al[@b63-ppa-11-305]   1   1   1   1   1   1   1   1   1     100
  Walker et al[@b68-ppa-11-305]           1   0   1   0   0   1   0   1   n/a   50
  Wickersham et al[@b41-ppa-11-305]       1   0   1   1   1   1   1   0   0     67
  Wigertz et al[@b37-ppa-11-305]          1   1   1   1   1   1   1   0   1     89
  Wouters et al[@b29-ppa-11-305]          0   0   1   0   1   1   1   0   n/a   50
  Wu et al[@b58-ppa-11-305]               1   1   1   1   1   1   1   0   0     78
  Ziller et al[@b96-ppa-11-305]           1   0   1   1   0   1   0   0   0     44
  Zeeneldin et al[@b97-ppa-11-305]        1   0   0   1   0   0   1   0   n/a   38

**Notes:** A: Are the main features of the study population described? B: Is participation \>80% or 60%--80% with no difference between responders and nonresponders? C: Is adherence measured appropriately and clearly described? D: Are other outcome variables measured appropriately? E: Did the analysis control for confounding? F: Are quantitative measures of association presented? G: Was the number of cases in the multivariate analysis at least ten times the number of independent variables in the final model? H: Was physician recommended nonadherence removed? I: Were losses of patients to follow-up taken into account?

**Abbreviation:** n/a, not applicable.

###### 

Results from included studies

  Predictor variables                                                                   Number of studies finding positive/negative effect                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ------------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Clinical variables**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Menopausal status (pre vs post)                                                       No effects: 3                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 4    Positive: 0                                                                                                                                                                                         Negative: 1[@b35-ppa-11-305]
  Laterality                                                                            No effects: 1                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 2    Positive: 0                                                                                                                                                                                         Negative: 0
  Larger tumor size                                                                     No effects: 1                                        Positive: 1[@b37-ppa-11-305]                                                                                                                                       Negative: 0                                                                                                                                                                                                              No effects: 10   Positive: 0                                                                                                                                                                                         Negative: 0
  More advanced stage                                                                   No effects: 12                                       Positive: 1[@b36-ppa-11-305]                                                                                                                                       Negative: 2[@b23-ppa-11-305],[@b33-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                                                No effects: 12   Positive: 2[@b64-ppa-11-305],[@b92-ppa-11-305]                                                                                                                                                      Negative: 2[@b24-ppa-11-305],[@b60-ppa-11-305]
  Positive lymph node status                                                            No effects: 3                                        Positive: 0                                                                                                                                                        Negative: 1[@b8-ppa-11-305]                                                                                                                                                                                              No effects: 8    Positive: 3[@b11-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b51-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b93-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}   Negative: 1[@b26-ppa-11-305]
  Radiotherapy                                                                          No effects: 11                                       Positive: 1[@b33-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                            Negative: 2[@b23-ppa-11-305],[@b58-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                                                No effects: 10   Positive: 2[@b8-ppa-11-305],[@b56-ppa-11-305]                                                                                                                                                       Negative: 1[@b24-ppa-11-305]
  Chemotherapy                                                                          No effects: 9                                        Positive: 3[@b38-ppa-11-305],[@b39-ppa-11-305],[@b58-ppa-11-305]                                                                                                   Negative: 3[@b23-ppa-11-305],[@b33-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b95-ppa-11-305]                                                                                                              No effects: 13   Positive: 5[@b8-ppa-11-305],[@b35-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b49-ppa-11-305],[@b64-ppa-11-305],[@b91-ppa-11-305]                                                      Negative: 2[@b24-ppa-11-305],[@b26-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}
  Surgery (yes/no)                                                                      No effects: 3                                        Positive: 1[@b23-ppa-11-305]                                                                                                                                       Negative: 0                                                                                                                                                                                                              No effects: 2    Positive: 1[@b24-ppa-11-305]                                                                                                                                                                        Negative: 0
  Mastectomy (yes/no)                                                                   No effects: 0                                        Positive: 1[@b34-ppa-11-305]                                                                                                                                       Negative: 1[@b9-ppa-11-305]                                                                                                                                                                                              No effects: 0    Positive: 1[@b49-ppa-11-305]                                                                                                                                                                        Negative: 0
  BCS (vs mastectomy)                                                                   No effects: 10                                       Positive: 1[@b33-ppa-11-305]                                                                                                                                       Negative: 2[@b8-ppa-11-305],[@b39-ppa-11-305]                                                                                                                                                                            No effects: 13   Positive: 0                                                                                                                                                                                         Negative: 2[@b8-ppa-11-305],[@b11-ppa-11-305]
  Positive HR status                                                                    No effects: 3                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 5    Positive: 3[@b11-ppa-11-305],[@b47-ppa-11-305],[@b48-ppa-11-305]                                                                                                                                    Negative: 0
  AIs (vs TAM)                                                                          No effects: 5                                        Positive: 4[@b35-ppa-11-305],[@b36-ppa-11-305],[@b38-ppa-11-305],[@b39-ppa-11-305]                                                                                 Negative: 4[@b23-ppa-11-305],[@b58-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b67-ppa-11-305],[@b90-ppa-11-305]                                                                                            No effects: 6    Positive: 2[@b49-ppa-11-305],[@b51-ppa-11-305]                                                                                                                                                      Negative: 1[@b90-ppa-11-305]
  Switching between TAM and AIs (vs not switching)                                      No effects: 0                                        Positive: 3[@b8-ppa-11-305],[@b38-ppa-11-305],[@b39-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                         Negative: 7[@b23-ppa-11-305],[@b28-ppa-11-305],[@b33-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b34-ppa-11-305],[@b35-ppa-11-305]                                                                          No effects: 1    Positive: 2[@b8-ppa-11-305],[@b43-ppa-11-305]                                                                                                                                                       Negative: 2[@b24-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b62-ppa-11-305]
  Presence of comorbidities                                                             No effects: 9                                        Positive: 3[@b9-ppa-11-305],[@b46-ppa-11-305],[@b69-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                         Negative: 5[@b8-ppa-11-305],[@b27-ppa-11-305],[@b30-ppa-11-305],[@b31-ppa-11-305],[@b34-ppa-11-305]                                                                                                                      No effects: 13   Positive: 2[@b50-ppa-11-305],[@b92-ppa-11-305]                                                                                                                                                      Negative: 7[@b7-ppa-11-305],[@b8-ppa-11-305],[@b10-ppa-11-305],[@b11-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b30-ppa-11-305],[@b62-ppa-11-305],[@b63-ppa-11-305]
  Diabetes/osteoporosis                                                                 No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 3[@b43-ppa-11-305]--[@b45-ppa-11-305]                                                                                                                                                     Negative: 0
  **Health care variables**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Mastologist visits                                                                    No effects: 0                                        Positive: 1[@b23-ppa-11-305]                                                                                                                                       Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 1[@b24-ppa-11-305]                                                                                                                                                                        Negative: 0
  Oncologist (vs no oncologist)                                                         No effects: 0                                        Positive: 2[@b9-ppa-11-305],[@b23-ppa-11-305]                                                                                                                      Negative: 0                                                                                                                                                                                                              No effects: 3    Positive: 2[@b24-ppa-11-305],[@b49-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                           Negative: 0
  Oncologist vs surgeon                                                                 No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 1    Positive: 0                                                                                                                                                                                         Negative: 0
  Nonsurgeon as provider                                                                No effects: 0                                        Positive: 1[@b36-ppa-11-305]                                                                                                                                       Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  Primary care vs oncologist/gynecologist                                               No effects: 1                                        Positive: 0                                                                                                                                                        Negative: 1[@b32-ppa-11-305]                                                                                                                                                                                             No effects: 2    Positive: 0                                                                                                                                                                                         Negative: 5[@b32-ppa-11-305],[@b43-ppa-11-305]--[@b45-ppa-11-305],[@b53-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}
  Oncologist vs gynecologist                                                            No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 1[@b60-ppa-11-305]
  More prescription medications                                                         No effects: 8                                        Positive: 2[@b33-ppa-11-305],[@b36-ppa-11-305]                                                                                                                     Negative: 0                                                                                                                                                                                                              No effects: 3    Positive: 5[@b7-ppa-11-305],[@b25-ppa-11-305],[@b26-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b54-ppa-11-305],[@b55-ppa-11-305]                                                      Negative: 1[@b32-ppa-11-305]
  Complementary/alternative medicine use                                                No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 1[@b7-ppa-11-305]
  90 days prescription refill period (vs 30 days)                                       No effects: 0                                        Positive: 1[@b8-ppa-11-305]                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 1[@b8-ppa-11-305]                                                                                                                                                                         Negative: 0
  More hospitalizations                                                                 No effects: 1                                        Positive: 0                                                                                                                                                        Negative: 3[@b23-ppa-11-305],[@b34-ppa-11-305],[@b36-ppa-11-305]                                                                                                                                                         No effects: 1    Positive: 0                                                                                                                                                                                         Negative: 3[@b24-ppa-11-305],[@b56-ppa-11-305],[@b57-ppa-11-305]
  Higher monthly costs                                                                  No effects: 2                                        Positive: 0                                                                                                                                                        Negative: 4[@b30-ppa-11-305],[@b32-ppa-11-305],[@b34-ppa-11-305],[@b52-ppa-11-305]                                                                                                                                       No effects: 3    Positive: 0                                                                                                                                                                                         Negative: 2[@b30-ppa-11-305],[@b32-ppa-11-305]
  **Demographic variables**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Family history                                                                        No effects: 2                                        Positive: 1[@b23-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                            Negative: 0                                                                                                                                                                                                              No effects: 2    Positive: 1[@b24-ppa-11-305]                                                                                                                                                                        Negative: 0
  Having children                                                                       No effects: 3                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 4    Positive: 0                                                                                                                                                                                         Negative: 0
  Secondary or higher education                                                         No effects: 13                                       Positive: 1[@b23-ppa-11-305]                                                                                                                                       Negative: 0                                                                                                                                                                                                              No effects: 15   Positive: 1[@b24-ppa-11-305]                                                                                                                                                                        Negative: 0
  Younger age (\<40/50 years)                                                           No effects: 3                                        Positive: 1[@b59-ppa-11-305]                                                                                                                                       Negative: 9[@b9-ppa-11-305],[@b23-ppa-11-305],[@b28-ppa-11-305],[@b31-ppa-11-305],[@b33-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b34-ppa-11-305],[@b38-ppa-11-305],[@b39-ppa-11-305],[@b58-ppa-11-305]   No effects: 6    Positive: 0                                                                                                                                                                                         Negative: 7[@b8-ppa-11-305],[@b24-ppa-11-305],[@b43-ppa-11-305],[@b44-ppa-11-305],[@b54-ppa-11-305],[@b60-ppa-11-305],[@b62-ppa-11-305]
  Older age (\>65/75 years)                                                             No effects: 5                                        Positive: 2[@b28-ppa-11-305],[@b60-ppa-11-305]                                                                                                                     Negative: 6[@b9-ppa-11-305],[@b30-ppa-11-305]--[@b33-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b59-ppa-11-305]                                                                                            No effects: 7    Positive: 1[@b49-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                                             Negative: 98,11,30,32,48,54,57,62,63
  Higher mean age (continuous)                                                          No effects: 9                                        Positive: 3[@b27-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b29-ppa-11-305],[@b67-ppa-11-305]                                                        Negative: 1[@b69-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                                                                  No effects: 4    Positive: 1[@b55-ppa-11-305]                                                                                                                                                                        Negative: 2[@b36-ppa-11-305],[@b64-ppa-11-305]
  Race (others vs Caucasian)                                                            No effects: 8                                        Positive: 0                                                                                                                                                        Negative: 2[@b9-ppa-11-305],[@b27-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                                                 No effects: 7    Positive: 0                                                                                                                                                                                         Negative: 1[@b30-ppa-11-305]
  Race (black vs Caucasian)                                                             No effects: 3                                        Positive: 0                                                                                                                                                        Negative: 4[@b8-ppa-11-305],[@b31-ppa-11-305],[@b32-ppa-11-305],[@b52-ppa-11-305]                                                                                                                                        No effects: 5    Positive: 0                                                                                                                                                                                         Negative: 0
  Race (Latina vs Caucasian)                                                            No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 1    Positive: 0                                                                                                                                                                                         Negative: 0
  Race (Hispanic vs Caucasian)                                                          No effects: 5                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 4    Positive: 1[@b11-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                                             Negative: 0
  Race (Asian vs Caucasian)                                                             No effects: 4                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 3    Positive: 1[@b8-ppa-11-305]                                                                                                                                                                         Negative: 0
  Race (less-acculturated Latina vs Caucasian)                                          No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 1[@b50-ppa-11-305]                                                                                                                                                                        Negative: 0
  Maori or Pacific vs NZ European                                                       No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 1[@b59-ppa-11-305]                                                                                                                                                                                             No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  With partner/married                                                                  No effects: 9                                        Positive: 6[@b8-ppa-11-305],[@b23-ppa-11-305],[@b32-ppa-11-305],[@b37-ppa-11-305],[@b52-ppa-11-305],[@b69-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}   Negative: 1[@b92-ppa-11-305]                                                                                                                                                                                             No effects: 7    Positive: 3[@b8-ppa-11-305],[@b24-ppa-11-305],[@b64-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                          Negative: 2[@b65-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b92-ppa-11-305]
  Perceived financial status/problems                                                   No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 1[@b35-ppa-11-305]                                                                                                                                                                                             No effects: 4    Positive: 0                                                                                                                                                                                         Negative: 0
  Lower income/net worth/SES                                                            No effects: 9                                        Positive: 0                                                                                                                                                        Negative: 4[@b30-ppa-11-305],[@b31-ppa-11-305],[@b68-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b69-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                 No effects: 7    Positive: 0                                                                                                                                                                                         Negative: 1[@b31-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}
  Smoking                                                                               No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 1[@b23-ppa-11-305]                                                                                                                                                                                             No effects: 1    Positive: 0                                                                                                                                                                                         Negative: 2[@b24-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b65-ppa-11-305]
  Alcohol                                                                               No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 1[@b23-ppa-11-305]                                                                                                                                                                                             No effects: 1    Positive: 0                                                                                                                                                                                         Negative: 1[@b24-ppa-11-305]
  Higher BMI                                                                            No effects: 1                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 4    Positive: 0                                                                                                                                                                                         Negative: 0
  **Psychosocial variables -- related to HT treatment and health care professionals**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Perceived efficacy of HT                                                              No effects: 1                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  HT concern beliefs                                                                    No effects: 6                                        Positive: 0                                                                                                                                                        Negative: 2[@b27-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b67-ppa-11-305]                                                                                                                                No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  HT necessity beliefs                                                                  No effects: 4                                        Positive: 3[@b35-ppa-11-305],[@b66-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b67-ppa-11-305]                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  Neutral or negative decisional balance score (beliefs)                                No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 2[@b25-ppa-11-305],[@b26-ppa-11-305]
  Coping appraisal (beliefs about HT efficacy and self-efficacy over costs)             No effects: 0                                        Positive: 1[@b69-ppa-11-305]                                                                                                                                       Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  Negative emotions about HT                                                            No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 2[@b35-ppa-11-305],[@b68-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                                                No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 1[@b35-ppa-11-305]
  Positive emotions about HT                                                            No effects: 1                                        Positive: 1[@b68-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                            Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 1[@b35-ppa-11-305]                                                                                                                                                                        Negative: 0
  Perceived importance of HT                                                            No effects: 0                                        Positive: 1[@b61-ppa-11-305]                                                                                                                                       Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  Adherence estimator (beliefs about efficacy, value and cost of HT)                    No effects: 0                                        Positive: 1[@b42-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                            Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  Symptom attribution                                                                   No effects: 1                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  Being involved in decision making/discussed HT with doctor                            No effects: 0                                        Positive: 0                                                                                                                                                        Positive: 0                                                                                                                                                                                                              No effects: 2    Positive: 1[@b48-ppa-11-305]                                                                                                                                                                        Negative: 0
  Not told about side effects                                                           No effects: 0                                        Positive: 0                                                                                                                                                        Positive: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 1[@b48-ppa-11-305]
  Patient--physician relationship                                                       No effects: 0                                        Positive: 1[@b35-ppa-11-305]                                                                                                                                       Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 1[@b35-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                                             Negative: 0
  Value of doctor's opinion                                                             No effects: 0                                        Positive: 1[@b61-ppa-11-305]                                                                                                                                       Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  Patient--physician communication                                                      No effects: 0                                        Positive: 1[@b67-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                            Negative: 0                                                                                                                                                                                                              No effects: 3    Positive: 2[@b50-ppa-11-305],[@b64-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                           Negative: 0
  Received right amount of support                                                      No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 1[@b48-ppa-11-305]                                                                                                                                                                        Negative: 0
  Being able to ask questions                                                           No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 1[@b10-ppa-11-305]                                                                                                                                                                        Negative: 0
  Self-efficacy in patient--physician interaction                                       No effects: 0                                        Positive: 1[@b27-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                            Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 1[@b50-ppa-11-305]                                                                                                                                                                        Negative: 0
  Understanding information                                                             No effects: 1                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 1[@b10-ppa-11-305]                                                                                                                                                                        Negative: 0
  Sufficient information given                                                          No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 1    Positive: 1[@b55-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                                             Negative: 0
  Perceived self-efficacy (learning about medication)                                   No effects: 0                                        Positive: 1[@b29-ppa-11-305]                                                                                                                                       Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  Perceived self-efficacy (taking medication)                                           No effects: 0                                        Positive: 3[@b27-ppa-11-305],[@b29-ppa-11-305],[@b69-ppa-11-305]                                                                                                   Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  Practical problems                                                                    No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 1[@b29-ppa-11-305]                                                                                                                                                                                             No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  **Psychosocial variables -- related to breast cancer**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Fear of cancer recurrence                                                             No effects: 3                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 2[@b10-ppa-11-305],[@b55-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                           Negative: 0
  High coherence beliefs                                                                No effects: 0                                        Positive: 1[@b46-ppa-11-305]                                                                                                                                       Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  Personal control, illness consequences                                                No effects: 1                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  Treatment control                                                                     No effects: 0                                        Positive: 1[@b46-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                            Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 0
  Perceived agism in cancer care                                                        No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 1[@b64-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}
  **General psychosocial variables**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Quality of life/emotional health                                                      No effects: 2                                        Positive: 0                                                                                                                                                        Negative: 1[@b40-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                                                                  No effects: 5    Positive: 0                                                                                                                                                                                         Negative: 0
  Optimism                                                                              No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 1[@b64-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                                             Negative: 0
  Fatalism                                                                              No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 1    Positive: 0                                                                                                                                                                                         Negative: 0
  Anxiety                                                                               No effects: 4                                        Positive: 0                                                                                                                                                        Negative: 1[@b40-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                                                                                                  No effects: 1    Positive: 0                                                                                                                                                                                         Negative: 1[@b49-ppa-11-305]
  Depression                                                                            No effects: 3                                        Positive: 0                                                                                                                                                        Negative: 3[@b34-ppa-11-305],[@b40-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b41-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"}                                                                   No effects: 5    Positive: 2[@b43-ppa-11-305],[@b44-ppa-11-305]                                                                                                                                                      Negative: 1[@b35-ppa-11-305]
  Low social support                                                                    No effects: 1                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 3[@b10-ppa-11-305],[@b64-ppa-11-305][\*](#tfn4-ppa-11-305){ref-type="table-fn"},[@b70-ppa-11-305]
  Cognitive impairments                                                                 No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 2    Positive: 0                                                                                                                                                                                         Negative: 1[@b54-ppa-11-305]
  Expressing a desire for future fertility                                              No effects: 0                                        Positive: 0                                                                                                                                                        Negative: 0                                                                                                                                                                                                              No effects: 0    Positive: 0                                                                                                                                                                                         Negative: 1[@b65-ppa-11-305]

**Note:**

The effect was not significant in multivariate analysis or was not tested in multivariate analysis.

**Abbreviations:** AIs, aromatase inhibitors; BCS, breast-conserving surgery; BMI, body mass index; HR, hormone receptor; HT, hormone therapy; SES, socioeconomic status; TAM, tamoxifen.

###### 

Relationship between side effects and HT adherence/persistence

  Variable                                                                                                                               Number of studies showing positive/negative effect                                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------
  Any side effects                                                                                                                       2× negative[@b27-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"},[@b29-ppa-11-305]                                              3× negative[@b35-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"},[@b46-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"},[@b47-ppa-11-305]
  3× no effects                                                                                                                          2× no effects                                                                                                                          
  Severe side effects                                                                                                                    0                                                                                                                                      2× negative[@b25-ppa-11-305],[@b48-ppa-11-305]
                                                                                                                                         1× no effects                                                                                                                          
  Overall hormone/menopause related                                                                                                      0                                                                                                                                      1× positive[@b51-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"}
                                                                                                                                         2× negative[@b10-ppa-11-305],[@b50-ppa-11-305]                                                                                         
  Hot flushes/vasomotor symptoms/sweating                                                                                                5× no effects                                                                                                                          1× positive[@b48-ppa-11-305]
                                                                                                                                         1× negative[@b49-ppa-11-305]                                                                                                           
                                                                                                                                         1× no effects                                                                                                                          
  Overall sleep/fatigue related                                                                                                          2× no effects                                                                                                                          2× no effects
  Gynecological symptoms                                                                                                                 1× positive[@b42-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"}                                                                1× positive[@b51-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"}
  2× negative[@b40-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"},[@b41-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"}   2× no effects                                                                                                                          
  3× no effects                                                                                                                                                                                                                                                                 
  Sex-related symptoms                                                                                                                   4× no effects                                                                                                                          2× no effects
  Joint aches and pains/osteoporosis                                                                                                     2× negative[@b40-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"},[@b41-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"}   2× no effects
  2× no effects                                                                                                                                                                                                                                                                 
  Weight concerns                                                                                                                        2× negative[@b40-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"},[@b41-ppa-11-305]                                              1× no effects
  1× no effects                                                                                                                                                                                                                                                                 
  Incontinence/ladder control                                                                                                            3× no effects                                                                                                                          1× no effects
  Hair thinning/loss                                                                                                                     0                                                                                                                                      1× positive[@b51-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"}
  Headaches                                                                                                                              0                                                                                                                                      1× negative[@b51-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"}
  Loss of appetite                                                                                                                       0                                                                                                                                      1× negative[@b51-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"}
  Gastrointestinal symptoms                                                                                                              2× no effects                                                                                                                          0
  Cognitive symptoms                                                                                                                     2× negative[@b40-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"},[@b41-ppa-11-305][\*](#tfn7-ppa-11-305){ref-type="table-fn"}   0
                                                                                                                                         1× no effects                                                                                                                          

**Notes:** Individual symptoms that were only tested in one study and were not significant are not listed (shortness of breath, eyesight changes, breast sensitivity, fractures/broken bones and retaining water).

The effect was not significant in multivariate analysis or was not tested in multivariate analysis.

**Abbreviation:** HT, hormone therapy.
